Hydroxypropyl beta-cyclodextrin compositions and methods
This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
1. A method for treating Niemann-Pick disease Type C in a pediatric human patient, the method comprising administering to the pediatric human patient 6 years of age or younger a pharmaceutical composition comprising a mixture of hydroxypropyl beta-cyclodextrin molecules, wherein the pharmaceutical composition is administered intrathecally or intracerebroventricularly in a dosage of about 500 mg to about 1500 mg.
2. The method of claim 1 , wherein the dosage is about 500 mg to about 1200 mg.
3. The method of claim 1 , wherein the dosage is about 800 mg to about 1000 mg.
4. The method of claim 1 , wherein the mixture of hydroxypropyl beta-cyclodextrin molecules has an average molar substitution of 0.40 to 0.80.
5. The method of claim 4 , wherein the average molar substitution of the mixture of hydroxypropyl beta-cyclodextrin molecules is 0.48 to 0.72.
6. The method of claim 4 , wherein the average molar substitution of the mixture of hydroxypropyl beta-cyclodextrin molecules is 0.58 to 0.68.
7. The method of claim 1 , wherein the pharmaceutical composition is administered every week, every two weeks, every three weeks, every month, every two months, or every three months.
8. The method of claim 1 , wherein the pharmaceutical composition is administered every two weeks.
9. The method of claim 1 , wherein the pharmaceutical composition is administered intrathecally via a lumbar injection.
10. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
11. The method of claim 10 , wherein the pharmaceutically acceptable carrier is an aqueous solution.
12. The method of claim 11 , wherein the aqueous solution is an isotonic saline solution.
13. The method of claim 1 , wherein pediatric patient is less than 2 years of age.
14. The method of claim 1 , wherein the Niemann-Pick disease Type C is Niemann-Pick disease Type C1 (NPC1) or Niemann-Pick disease Type C2 (NPC2).
15. The method of claim 1 wherein pediatric patient is from 2 years to 6 years of age.
16. The method of claim 1 , wherein the pediatric human patient's Niemann-Pick disease is characterized as early-infantile onset.
17. The method of claim 1 , wherein the pediatric human patient's Niemann-Pick disease is characterized as late-infantile onset.
18. The method of claim 1 , wherein the mixture of hydroxypropyl beta-cyclodextrin molecules has an average molar substitution of 0.67, 0.68, 0.69, 0.70, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, or 0.80.
19. The method of claim 1 , wherein the mixture of hydroxypropyl beta-cyclodextrin molecules has an average degree of substitution (DSa) of 6.8±0.2.
20. The method of claim 1 , wherein the mixture of hydroxypropyl beta-cyclodextrin molecules has an average degree of substitution (DSa) 6.9±0.1.